Get the Stockscreener App
1.3954
6.04%
0.0754
Calidi Biotherapeutics Inc stock is traded at $1.3954, with a volume of 2.38M.
It is up +6.04% in the last 24 hours and up +32.05% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$1.32
Open:
$1.39
24h Volume:
2.38M
Relative Volume:
6.05
Market Cap:
$16.70M
Revenue:
-
Net Income/Loss:
$-23.36M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+29.60%
1M Performance:
+32.05%
6M Performance:
-28.95%
1Y Performance:
-92.82%
1-Day Range:
$1.27
$1.55
1-Week Range:
$1.03
$1.55
52-Week Range:
$0.73
$26.30
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Biotherapeutics’ $2.1 Million Shares Offering - Global Legal Chronicle
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Calidi Biotherapeutics (NYSE:CLDI) - Defense World
CLDICalidi Biotherapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Calidi to present data supporting RTNova at upcoming conferences - TipRanks
SEC Form 424B5 filed by Calidi Biotherapeutics Inc. - Quantisnow
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences - The Manila Times
Calidi to sell 2.05M shares at $1.00 in registered direct offering - Yahoo Finance
Calidi Biotherapeutics stock tumbles on $2M securities offering - MSN
CLDI stock touches 52-week low at $0.95 amid sharp annual decline By Investing.com - Investing.com South Africa
CLDI stock touches 52-week low at $0.95 amid sharp annual decline - Investing.com
Why Calidi Biotherapeutics (CLDI) Stock Is Down 13% - Benzinga
Calidi Biotherapeutics secures $2 million in equity financing - Investing.com
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement - The Manila Times
Calidi Biotherapeutics Faces Warrant Delisting by NYSE - Yahoo Finance
NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) - ForexTV.com
Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Exchange Income Corp (EIF-T) QuotePress Release - The Globe and Mail
Cocoa #7 (CAU21) Quote - The Globe and Mail
Wendy Pizarro - Los Angeles Times
CLDI stock touches 52-week low at $1 amid market challenges - Investing.com Canada
Adv Micro Devices (AMD-Q) QuotePress Release - The Globe and Mail
Calidi Biotherapeutics Gains FDA Nod for Brain Cancer Trial - TipRanks
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 - U.S. Politics Today
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma - The Manila Times
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application - The Bakersfield Californian
Calidi Biotherapeutics announces board changes and auditor ratification - Investing.com
Calidi Biotherapeutics Presents Antitumor Virotherapy Advances - TipRanks
Calidi Biotherapeutics stock target cut by Baird with Outperform tag maintained - Investing.com
Calidi price target lowered to $2.50 from $20 at Baird - TipRanks
CLDI Stock Earnings: Calidi Biotherapeutics Beats EPS for Q2 2024 - MSN
Calidi Biotherapeutics Inc (CLDI) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
CLDI Stock Plummets to 52-Week Low at $1.41 Amid Market Turbulence - Investing.com
Calidi Biotherapeutics Unveils Redtail Biopharma Subsidiary - TipRanks
Calidi Biotherapeutics announces board reduction following director's exit By Investing.com - Investing.com South Africa
Calidi Biotherapeutics announces board reduction following director's exit - Investing.com
Calidi Biotherapeutics Board Reshuffles as Advisor Departs - TipRanks
Calidi Biotherapeutics (NYSE:CLDI) Releases Earnings Results - Defense World
Calidi Biotherapeutics (NYSE:CLDI) Issues Quarterly Earnings Results - MarketBeat
Why Calidi Biotherapeutics is Moving Higher Monday - MSN
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results - BioSpace
Biotech Spins Off Subsidiary for Stem Cell Therapy - San Diego Business Journal
UMACUnusual Machines, Inc. Latest Stock News & Market Updates - StockTitan
GreenPower Motor and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - AccessWire
Metric Analysis: Calidi Biotherapeutics Inc (CLDI)’s Key Ratios in the Limelight - The Dwinnex
CLDI’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Calidi Biotherapeutics Secures Investment, Expands Advisory Board - TipRanks
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Cap:
|
Volume (24h):